Literature DB >> 12495681

Reappraisal of attributable mortality in critically ill patients with nosocomial bacteraemia involving Pseudomonas aeruginosa.

S Blot1, K Vandewoude, E Hoste, F Colardyn.   

Abstract

In a retrospective study, population characteristics and outcome were investigated in intensive care unit (ICU) patients with hospital-acquired Pseudomonas aeruginosa bacteraemia admitted over a seven-year period (January 1992 through December 1998). A matched cohort study was performed in which all ICU patients with P. aeruginosa bacteraemia were defined as cases (N=53). Matching (1:2 ratio) of the controls (N=106) was based on the APACHE II classification: an equal APACHE II score (+/-1 point) and an equal diagnostic category. Patients with P. aeruginosa bacteraemia had a higher incidence of acute respiratory failure, haemodynamic instability, a longer ICU stay and length of ventilator dependence (P<0.05). In-hospital mortalities for cases and controls were 62.3 vs. 47.2% respectively (P=0.073). Thus, the attributable mortality was 15.1% (95% confidence intervals: -1.0-31.2). In a multivariate survival analysis the APACHE II score was the only variable independently associated with mortality. In conclusion, P. aeruginosa bacteraemia is associated with a clinically relevant attributable mortality (15%). However, we could not find statistical evidence of P. aeruginosa being an independent predictor of mortality.

Entities:  

Mesh:

Year:  2003        PMID: 12495681     DOI: 10.1053/jhin.2002.1329

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  14 in total

1.  Invasive devices: no need? No use!

Authors:  Stijn I Blot; Renaat Peleman; Koenraad H Vandewoude
Journal:  Intensive Care Med       Date:  2006-12-05       Impact factor: 17.440

2.  Impact of piperacillin resistance on the outcome of Pseudomonas ventilator-associated pneumonia.

Authors:  Alain Combes; Charles-Edouard Luyt; Jean-Yves Fagon; Michel Wolff; Jean-Louis Trouillet; Jean Chastre
Journal:  Intensive Care Med       Date:  2006-09-07       Impact factor: 17.440

3.  Population-based study of the epidemiology and the risk factors for Pseudomonas aeruginosa bloodstream infection.

Authors:  M D Parkins; D B Gregson; J D D Pitout; T Ross; K B Laupland
Journal:  Infection       Date:  2009-12-12       Impact factor: 3.553

4.  Incidence of Pseudomonas aeruginosa bacteremia: a population-based study.

Authors:  Majdi N Al-Hasan; John W Wilson; Brian D Lahr; Jeanette E Eckel-Passow; Larry M Baddour
Journal:  Am J Med       Date:  2008-08       Impact factor: 4.965

5.  Morbidity associated with Pseudomonas aeruginosa bloodstream infections.

Authors:  Marc H Scheetz; Michael Hoffman; Maureen K Bolon; Grant Schulert; Wendy Estrellado; Ioannis G Baraboutis; Padman Sriram; Minh Dinh; Linda K Owens; Alan R Hauser
Journal:  Diagn Microbiol Infect Dis       Date:  2009-04-02       Impact factor: 2.803

6.  Antibiotic management of suspected nosocomial ICU-acquired infection: does prolonged empiric therapy improve outcome?

Authors:  Mary-Anne W Aarts; Christian Brun-Buisson; Deborah J Cook; Anand Kumar; Steven Opal; Graeme Rocker; Terry Smith; Jean-Louis Vincent; John C Marshall
Journal:  Intensive Care Med       Date:  2007-06-09       Impact factor: 17.440

7.  Bacterial and clinical characteristics of health care- and community-acquired bloodstream infections due to Pseudomonas aeruginosa.

Authors:  Angela Hattemer; Alan Hauser; Maureen Diaz; Marc Scheetz; Nirav Shah; Jonathan P Allen; Jahan Porhomayon; Ali A El-Solh
Journal:  Antimicrob Agents Chemother       Date:  2013-06-03       Impact factor: 5.191

8.  Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas aeruginosa bacteremia.

Authors:  Ioannis A Bliziotis; Nicola Petrosillo; Argyris Michalopoulos; George Samonis; Matthew E Falagas
Journal:  PLoS One       Date:  2011-10-26       Impact factor: 3.240

9.  Acquired bloodstream infection in the intensive care unit: incidence and attributable mortality.

Authors:  John R Prowle; Jorge E Echeverri; E Valentina Ligabo; Norelle Sherry; Gopal C Taori; Timothy M Crozier; Graeme K Hart; Tony M Korman; Barrie C Mayall; Paul D R Johnson; Rinaldo Bellomo
Journal:  Crit Care       Date:  2011-03-21       Impact factor: 9.097

10.  Dynorphin activates quorum sensing quinolone signaling in Pseudomonas aeruginosa.

Authors:  Olga Zaborina; Francois Lepine; Gaoping Xiao; Vesta Valuckaite; Yimei Chen; Terry Li; Mae Ciancio; Alex Zaborin; Elaine O Petrof; Elaine Petroff; Jerrold R Turner; Laurence G Rahme; Eugene Chang; John C Alverdy
Journal:  PLoS Pathog       Date:  2007-03       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.